Results 171 to 180 of about 9,514 (200)

Life after hypomethylating agents in myelodysplastic syndrome

Current Opinion in Hematology, 2015
Hypomethylating agents, azacitidine and decitabine, are successfully used for the treatment of myelodysplastic syndromes (MDS). In spite of improvement in survival, MDS is still incurable without hematopoietic stem cell transplant, and in case of absence/loss of response to hypomethylating agents, outcome is poor.
openaire   +3 more sources

[Hypomethylating agents for the treatment of myelodysplastic syndromes].

Bulletin du cancer, 2011
Azacitidine has been approved in January 2009 in Europe in the treatment of higher-risk myelodysplastic syndromes (MDS). This represents the first time a drug is specifically labelled in MDS in Europe, and is a cornerstone in the development of hypomethylating agents 5-azacytidine (azacitidine) and 5-deoxyazacytidine (decitabine).
Raphael, Itzykson, Pierre, Fenaux
openaire   +1 more source

Acute Myocarditis Induced by Hypomethylating Agents

Journal of Clinical Oncology, 2011
Jean-Emmanuel, Bibault, Nathalie, Cambier, Jean-Michel, Lemahieu, Bruno, Quesnel, Marine, Auffret, Christian, Rose   +5 more
openaire   +2 more sources

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

Leukemia and Lymphoma, 2022
B Douglas Smith, Guillermo Garcia-Manero, Vincent Ribrag   +2 more
exaly  

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach

Cancers, 2023
Carmelo Gurnari, Amer M Zeidan, Jan Philipp Bewersdorf   +2 more
exaly  

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter

Frontiers in Oncology, 2021
Eleftheria Lamprianidou, Ioannis Kotsianidis, Kotsianidis Ioannis   +2 more
exaly  

Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies

Cancers, 2023
Gianluca Gaidano, Francesco Barone-Adesi, Andrea Patriarca   +2 more
exaly  

Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia

Journal of Internal Medicine, 2023
Guangyang Weng
exaly  

A safe and effective DNA hypomethylating agent

Nature Reviews Drug Discovery, 2021
openaire   +1 more source

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

Frontiers in Oncology, 2021
Qian Wang
exaly